

• **Name:** Min Hwan Kim

• **Current Position:** Clinical Professor

• **Country:** Republic of Korea

• **Educational Background:**

2003.3 ~ 2009.2 M.D., Yonsei University College of Medicine, Seoul, Korea

2012.3 ~ 2014.2 M.S., Department of Medicine, Yonsei University College of Medicine

2014.3 ~ 2017.9 Ph.D. Graduate School of Medical Science and Engineering, KAIST,
Daejeon, Korea

• **Professional Experience:**

2017.9 ~ 2018.2 PostDoc, Graduate School of Medical Science and Engineering, KAIST

2018.03~ 2019.2 Clinical Fellow, Division of Medical Oncology, Department of Internal Medicine, Yonsei
Cancer Center, Yonsei University College of Medicine

2019.03~ current Clinical Professor, Division of Medical Oncology, Department of Internal Medicine,
Yonsei Cancer Center, Yonsei University College of Medicine

• **Professional Organizations:**

Associate Member of Korean Society of Medical Oncology

Member of Korean Cancer Association

Member of Korean Cancer Study Group

Associate member of American Association for Cancer Research

Member of American Society of Clinical Oncology

Member of Korean Association of Internal Medicine

Reviewer of PlosOne

Reviewer of Lung Cancer

• **Main Scientific Publications:**

Kim MH, Jang M, Kim H, Lee WJ, Kang CM, Choi HJ. Distinct immunological properties of the two
histological subtypes of adenocarcinoma of the ampulla of Vater, Cancer Immunol Immunother. 2019 Jan 2.

Kim MH, Zhang X, Jung M, Jung I, Park HS, Beom SH, Kim HS, Rha SY, Kim H, Choi YY, Son T, Kim HI,
Cheong JH, Hyung WJ, Noh SH, Chung HC, Immunohistochemistry biomarkers predict survival in stage II/III
gastric cancer patients: from a prospective clinical trial, Cancer Res Treat, 2018

Kim MH, Kim CG, Kim SK, Shin SJ, Choe EA, Park SH, Shin EC, Kim J. YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma. *Cancer Immunol Res.* 2018 Jan 30

Kim MH, Kim J. Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies. *Cell Mol Life Sci.* 2017 Apr;74(8):1457-1474 (First Author and Co-corresponding Author)

Kim MH, Kim J, Hong H, Lee SH, Lee JK, Jung E, Kim J, Actin Remodeling Confers BRAF Inhibitor Resistance to Melanoma Cells through YAP/TAZ Activation, *The EMBO Journal* 2016 Mar 1;35(5):462-78 (Journal Cover)

Kim MH, Lee S, Koo JS, Jung KH, Park IH, Jeong J, Kim SI, Park S, Park HS, Park BW, Kim JH, Sohn J., Anaplastic lymphoma kinase gene copy number gain in inflammatory breast cancer (IBC): prevalence, clinicopathologic features and prognostic implication. *PLoS One.* 2015 Mar 24;10(3)

Kim MH, Shim HS, Kang DR, Jung JY, Lee CY, Kim DJ, Lee JG, Bae MK, Kim HR, Lim SM, Kim EY, Park JS, Chung KY, Kim HJ, Kim JH, Cho BC., Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma., *Lung Cancer.* 2014 Mar;83(3):389-95.

Kim MH, Kim HR, Cho BC, Bae MK, Kim EY, Lee CY, Lee JS, Kang DR, Kim JH., Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations., *Lung Cancer.* 2014 May;84(2):196-202.

Kim MH, Koo JS, Lee S., FOXP3 expression is related to high Ki-67 index and poor prognosis in lymph node-positive breast cancer patients., *Oncology.* 2013;85(2):128-36.